Regeneron Reports Phase 3 RELATIVITY-020 Results for Fianlimab in Advanced Melanoma

Regeneron today announced results from the Phase 3 RELATIVITY-020 trial evaluating fianlimab plus cemiplimab versus pembrolizumab in patients with previously untreated advanced melanoma. The trial met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival for fianlimab plus cemiplimab. Fianlimab is an anti-LAG-3 antibody that, when combined with anti-PD-1 therapy, provides dual checkpoint blockade. These results support fianlimab plus cemiplimab as a potential new standard of care in first-line advanced melanoma.